Sector News

Sanofi pumps €50M into rising French VC shop Jeito

November 15, 2020
Life sciences

Sanofi has invested €50 million ($59 million) in French VC firm Jeito Capital. The investment, Sanofi’s first in a private French fund, boosts Rafaèle Tordjman’s efforts to establish Jeito as an emerging force in the European biotech VC scene.

Tordjman spent 16 years as a managing partner at Sofinnova Partners before leaving and founding Jeito in 2017. Jeito flew below the radar in its early years. That changed in January when Jeito broke cover with €200 million in cash from institutional investors and family offices. Since then, Jeito has disclosed two of the approximately 15 investments it plans to make using the money.

In September, Jeito co-led a $110 million series A financing in Neogene Therapeutics, a transatlantic developer of fully personalized neo-antigen T cell therapies. The next month, Jeito participated in a €44.5 million investment in French gene therapy startup SparingVision. Sanofi has signed up to help Jeito make more bets and, in doing so, strengthen its ties to the European biotech scene.

“This investment provides Sanofi with access to the very best in French and European healthcare innovation and reinforces our commitment to investing in our medium and long-term development pipeline,” Sanofi CEO Paul Hudson said in a statement.

Hudson went on to say Sanofi strongly believes France and the rest of Europe have the potential to become a world-class hub for life science innovation, provided “the appropriate conditions and a stimulating environment” they need to thrive are in place. The comments come months after a report that Sanofi is set to ax up to 1,680 jobs in Europe, including 1,000 in France, its home market.

Sanofi previously worked with Bpifrance, the French investment bank, to set up two public-private investment funds focused on the life sciences industry in France and the rest of Europe. Jeito is the first private French fund to receive investment from Sanofi.

by Nick Paul Taylor

Source: fiercebiotech.com

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”